If it can bounce back and generate solid returns in the next five years, now is about as good a time as any to invest in the company. But how likely is that? Let's find out how things might evolve for ...
Most AI-driven biopharma companies parse available data to find drug molecules that target single proteins believed to underlie a disease. This yields a lot of leads, but few pan out. Recursion ...
Talk of AI is everywhere, especially in healthcare. Companies are flooding into the space, promising to solve age-old problems by revolutionizing how prescription drugs are made and sold. A very ...
Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback